Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Diversity, Equity, & Inclusion (DEI)
    • Neurology: Clinical Practice Accelerator
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
    • UDDA Revision Series
  • Podcast
  • CME
  • About
    • About the Journals
    • Editorial Boards
    • Contact Us
  • Authors
    • Submit Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Diversity, Equity, & Inclusion (DEI)
    • Neurology: Clinical Practice Accelerator
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
    • UDDA Revision Series
  • Podcast
  • CME
  • About
    • About the Journals
    • Editorial Boards
    • Contact Us
  • Authors
    • Submit Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Resident & Fellow Section

User menu

  • Subscribe
  • My Alerts
  • Log in

Search

  • Advanced search
American Academy of Neurology Journals
Home
  • Subscribe
  • My Alerts
  • Log in
Site Logo

Alzheimer disease

  • Aducanumab Resources

    The US Food and Drug Administration (FDA) announced on June 7, 2021, the approval of aducanumab (Aduhelm). The drug was approved under the Accelerated Approval pathway, one of the alternative drug approval pathways.

    In addition to our latest articles on Alzheimer disease, Neurology has included a list of aducanumab resources on this page to help our members stay informed on the current landscape of the new Alzheimer disease drug.

      Featured Editorials and Viewpoints

     

     

    Aducanumab: Making Sense of the Cents
    Gregory S. Day, MD, MSc, MSCI, FAAN

    Inevitably, the assumptions that guide cost-effectiveness calculations for any one patient will be as diverse and unique as the patient in question. Thus, we must be prepared to guide our patients with early symptomatic AD in this decision-making process, helping them to weigh uncertain benefits, risks, and costs associated with the use of aducanumab and other forthcoming treatments for AD. [Read Article]

    Practical Considerations in the Administration of Aducanumab for the Neurologist
    Katherine Coerver, Melissa M Yu, Anelyssa D'Abreu, Marc Wasserman, Kavita Nair

    The decision by the FDA to approve aducanumab remains controversial and its administration will pose many challenges that will be new to neurologists, despite extensive experience with prior intravenous medications. [Read Article]

    Decisions With Patients and Families Regarding Aducanumab in Alzheimer Disease, With Recommendations for Consent: AAN Position Statement
    Winston Chiong, Benjamin David Tolchin, Richard J. Bonnie, et al.

    Neurologists, patients and families will face ethical challenges given the incomplete data available to guide aducanumab prescribing, the prospect of worrisome financial conflicts of interest, and the costs and practical burdens that using aducanumab will impose on patients and families. Neurologists facing these challenges will be guided best by established ethical principles that they can apply, in turn, to transparently counsel patients and their families. [Read Article]

    Aducanumab for Dementia
    Brian C. Callaghan

    In contrast to the unknown and unlikely efficacy, aducanumab has known serious side effects and high costs. Given the large downsides and unclear and unlikely benefits, I strongly support ICER’s report that states that there is insufficient evidence to support approval of aducanumab without further studies. [Read Article]


    Clinical Efficacy, Drug Safety and Surrogate Endpoints: Has Aducanumab Met All of Its Expectations?
    Linda A. Hershey, Rawan Tarawneh

    ...the patient and their caregivers need to understand that the clinical benefits of aducanumab are small and that more data will be needed in the future to determine whether these benefits are clinically or functionally meaningful to patients. [Read Article]


    Aducanumab, Amyloid Lowering, and Slowing of Alzheimer Disease
    Stephen Salloway, Jeffrey Cummings

    Aducanumab opens a new era in AD research and care and provides a foundation for development of progressively better therapies. [Read Article]


    Prescribing Aducanumab in the Face of Meager Efficacy and Real Risks
    David S. Knopman, Joel S. Perlmutter

    On the one hand, neurologists want to offer hope. Yet, aducanumab’s benefits are meager, if even present and there are non-trivial risks of side effects. [Read Article]

     

     

      Aducanumab Podcasts












    View All Episodes

Latest Articles

  • Research Article
    Association Between Triglycerides and Risk of Dementia in Community-Dwelling Older AdultsA Prospective Cohort Study
    Zhen Zhou, Joanne Ryan, Andrew M. Tonkin, et al.
    Neurology October 25, 2023
  • Research Article
    Relevance of Minor Neuropsychological Deficits in Patients With Subjective Cognitive Decline
    Melina Stark, Steffen Wolfsgruber, Luca Kleineidam, et al.
    Neurology October 11, 2023
  • Research Article
    Association of Sleep Disturbances With Brain Amyloid and Tau Burden, Cortical Atrophy, and Cognitive Dysfunction Across the AD Continuum
    So Hoon Yoon, Han-Kyeol Kim, Jae-Hoon Lee, et al.
    Neurology October 09, 2023
  • Research Article
    Association of pathological and volumetric biomarker changes with cognitive decline in clinically normal adults: Harvard Aging Brain Study
    Bernard J Hanseeuw, Heidi I Jacobs, Aaron P Schultz, et al.
    Neurology November 15, 2023
Show more
Advertisement
  • AAN Aducanumab Resources

    Brain made of gears that are falling away.

    • AAN Aducanumab Resource Center
    • How to Talk to Your Patients About Aducanumab
    • Advocacy and Payer Relations

Hastening the Diagnosis of Amyotrophic Lateral Sclerosis

Dr. Brian Callaghan and Dr. Kellen Quigg

► Watch

  • Neurology Podcast - Over 16 million downloads!
    Neurology Podcast
    November Headache Series: Update on Neuromodulation
    Our 2023 November Headache series wraps up with Dr. Tesha Monteith talking with Dr. Stewart Tepper about rapid developments in neuromodulation. November 30, 2023.
    Neurology, Journal, Podcast
    Listen39:37
    Subscribe
    View Recent Podcasts
Site Logo
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Education
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

© 2023 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise